MedTrace Logo

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

NCT00610714 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2012-12-18

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer

Conditions

Interventions

DRUG

AZD0530

oral once daily dose

DRUG

Carboplatin

intravenous injection

DRUG

Paclitaxel

intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Chris Poole, Prof · Dept. of Oncology, University Hospital, Clifford Bridge Road, Walsgrave, Coventry

  • Mireille Cantarini, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-08-31
Completion
2012-01-31

Countries

  • Bulgaria
  • Canada
  • Denmark
  • France
  • Netherlands
  • Norway
  • Peru
  • Portugal
  • Romania
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00610714 on ClinicalTrials.gov